Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
COVID-19
Meningococcal disease
Pneumococcal disease
2023
2021
Americas
Clear all
Type of publications
NITAG documentation
(74)
Systematic reviews (SYSVAC)
(7)
Topics
Available to download in languages
Regions
Americas
(81)
Africa
(25)
Eastern Mediterranean
(2)
Europe
(96)
South-East Asia
(4)
Western Pacific
(21)
Countries
Argentina
(2)
Bolivia
(2)
Canada
(25)
Chile
(10)
United States of America
(41)
Diseases
COVID-19
(74)
Meningococcal disease
(3)
Pneumococcal disease
(4)
Dengue
(1)
Ebola
(1)
Hepatitis B
(1)
Herpes zoster
(1)
Human papillomavirus (HPV)
(6)
Influenza
(2)
Poliomyelitis
(1)
Rotavirus
(2)
RSV (Respiratory syncytial virus)
(5)
Vaccine topics
Acceptance
(3)
Coverage
(2)
Ethical issues
(3)
Safety
(1)
Target population
Adolescents
(1)
Adults
(4)
All age groups
(5)
Children
(3)
Healthcare workers
(1)
Newborn
(1)
Older adults
(2)
Parents/caregivers
(1)
Pregnant women
(5)
Publication date
2023
(16)
2021
(65)
2024
(3)
2022
(44)
2020
(64)
2019
(8)
2018
(9)
2017
(2)
2016
(10)
2015
(6)
2014
(8)
2013
(6)
2012
(2)
2011
(3)
2010
(5)
2009
(1)
2008
(3)
2007
(2)
2006
(3)
2005
(1)
2004
(2)
2003
(3)
2002
(2)
1997
(2)
81 results found
2023
∙
NACI
NACI Interim guidance on the use of bivalent Omicroncontaining COVID-19 vaccines for primary series
2023
∙
NACI
Guidance on an additional COVID-19 booster dose in the spring of 2023 for individuals at high risk of severe illness due to COVID-19
2023
∙
NACI
Recommendations on the use of conjugate pneumococcal vaccine – 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: Economic evidence supplementary appendix
2023
∙
NACI
Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines
2023
∙
NACI
Interim guidance on the use of pneumococcal 15-valent conjugate vaccine (PNEU-C-15) in pediatric populations
2023
∙
NACI
NACI guidance on COVID-19 vaccine booster doses: Initial considerations for 2023
2021
∙
Yasmin, F. Najeeb, H. Moeed, A. Naeem, U. Asghar, M. S. Chughtai, N. U. Yousaf, Z. Seboka, B. T. Ullah, I. Lin, C. Y. Pakpour, A. H.
COVID-19 Vaccine Hesitancy in the United States: A Systematic Review
2021
∙
Magesh, S. John, D. Li, W. T. Li, Y. Mattingly-App, A. Jain, S. Chang, E. Y. Ongkeko, W. M.
Disparities in COVID-19 Outcomes by Race, Ethnicity, and Socioeconomic Status: A Systematic-Review and Meta-analysis
2021
∙
Becerra-Culqui, T. A. Sy, L. S. Solano, Z. Tseng, H. F.
Real-world evidence of quadrivalent meningococcal conjugate vaccine safety in the United States: a systematic review
2021
∙
Wingert, Aireen Pillay, Jennifer Gates, Michelle Guitard, Samantha Rahman, Sholeh Beck, Andrew Vandermeer, Ben Hartling, Lisa
Risk factors for severity of COVID-19: a rapid review to inform vaccine prioritisation in Canada
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register